SEARCH

SEARCH BY CITATION

References

  • 1
    D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332 54.
  • 2
    Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991; 324: 1532 8.
  • 3
    Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981; 305: 1371 4.
  • 4
    Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2: 523 7.
  • 5
    Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou JP. Comparison of the effects of a cardioselective and nonselective beta-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528 31.
  • 6
    Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized clinical trial of propranolol versus placebo in the prevention of first variceal hemorrhage. Gastroenterology 1990; 99: 1401 7.
  • 7
    Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056 9.
  • 8
    Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624 9.
  • 9
    Bosch J, Mastai R, Kravetz D, et al. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200 5.
  • 10
    Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6: 101 6.
  • 11
    Vorobioff J, Picabea E, Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 648 53.
  • 12
    Albillos A, Perez-Paramo M, Cacho G, et al. Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol. J Hepatol 1997; 27: 496 504.
  • 13
    Mills PR, Rae AP, Farah DA, Russell RI, Lorimer AR, Carter DC. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25: 73 8.
  • 14
    Arthur MJP, Tanner AR, Patel C, Wright R, Renwick AG, George CF. Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut 1989; 26: 14 19.
  • 15
    Stark G, Stark U, Hönigl K, et al. The effects of the propranolol enantiomers on the intracardiac electrophysiological activities of Langendorff-perfused hearts. Basic Res Cardiol; 84: 461 8.
  • 16
    Stoschitzky K, Lindner W, Rath M, et al. Stereoselective hemodynamic effects of (R)- and (S)-propranolol in man. Naunyn-Schmiedeberg’s Arch Pharmacol 1989; 339: 474 8.
  • 17
    Stoschitzky K, Lindner W, Egginger G, et al. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: hemodynamic effects, plasma concentrations and influence on thyroid hormone levels. Clin Pharmacol Ther 1992; 51: 445 53.
  • 18
    Walle T, Webb JG, Bagwell E, Walle U, Daniell HB, Gaffney TE. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 1988; 37: 115 24.
  • 19
    Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: Evidence for disappearance of first-pass extraction. J Cardiovasc Pharmacol 1992; 19(Suppl. 1): S142 6.
  • 20
    Stahl E, Baumgartner U, Henke D, Schölmerich J, Mutschler E, Spahn-Langguth H. Rats with portacaval shunt as a potential experimental model for liver cirrhosis: application to carvedilol stereopharmacokinetics. Chirality 1993; 5: 1 7.
  • 21
    Branch RA, James J, Read AE. A study of factors influencing drug disposition in chronic liver disease using the model drug (+)-propranolol. Br J Clin Pharmacol 1976; 3: 243 9.
  • 22
    Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou JP. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 1978; 74: 566 71.
  • 23
    Spahn-Langguth H, Podkowik B, Stahl E, Martin E, Mutschler E. Improved enantiospecific RP-HPLC assays for Propranolol in plasma and urine with Pronethalol as internal standard. J Anal Toxicol 1991; 15: 327 31.
  • 24
    Lebrec C, Nouel O, Corbic M, Benhamou JP. Propranolol—a medical treatment for portal hypertension? Lancet 1980; 2: 180 2.
  • 25
    Shand DG & Ragno RE. The disposition of Propranolol I. Elimination during oral absorption in man. Pharmacology 1972; 7: 159 68.
  • 26
    Bercoff E, Bataille C, Pariente AE, Valla D, Delhotal B, Lebrec D. Assessment of β-adrenergic blockade with propranolol in patients with cirrhosis . Hepatology 1984; 4: 451 3.
  • 27
    Jiron M, Delhotal B, Lebrec D. Relationship between dose, blood level and haemodynamic response in patients with cirrhosis receiving propranolol. Eur J Clin Pharmacol 1985; 28: 353 5.
  • 28
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646 9.
  • 29
    Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F. Effect of aging on the pharmacokinetics of Acebutolol enantiomers. J Clin Pharmacol 1992; 32: 148 56.
  • 30
    Poynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987; 7: 447 51.